Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Tauopathies 1Neurodegenerative Diseases 1Neurocognitive Disorders 1Nervous System Diseases 1Mental Disorders 1Inflammation 1Dementia 1Central Nervous System Diseases 1Brain Diseases 1Alzheimer Disease 1

Interventions

epigallocatechin gallate 2Ascorbic Acid 2semaglutide 1microcrystalline cellulose 1dapagliflozin 1cytisine 1bupropion hydrochloride, naltrexone hydrochoride drug combination 1XENP 1595 1Vitamin D 1Topiramate 1Tirzepatide 1Spirometry 1Selenium 1Saline Solution 1Resistance Training 1Reperfusion 1Qsymia 1Probiotics 1Platelet Count 1Plastic Surgery Procedures 1Phentermine 1Naltrexone 1Losartan 1Liraglutide 1Ischemic Preconditioning 1Hematologic Tests 1Glucagon-Like Peptide-1 Receptor 1Endurance Training 1Diethylpropion 1Diet Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inflammation × XENP 1595 × 1 year × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡